NCT07674680 Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women
| NCT ID | NCT07674680 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Missouri-Columbia |
| Condition | Women |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-07-31 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2026-07-31 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
Eligibility Criteria
Inclusion Criteria: * Healthy women, * Assigned female at birth, * 18-70 years of age, * Body mass index \<18 or ≥30 kg/m2, Exclusion Criteria: * Assigned male at birth, * Pregnancy, * Breastfeeding, * History of hormone replacement therapy, chemical menopause, or oophor-ectomy * Polycystic ovarian syndrome or Primary ovarian insufficiency, * Current smoking/Nicotine use, * Blood pressure ≥140/90 mmHg, * Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy, * Nerve/neurologic disease, * Cardiovascular, hepatic, renal, respiratory disease, * Hypersensitivity to nitroglycerin, * Diabetes, * Communication barriers,
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07674680 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Women. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07674680 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07674680 currently recruiting?
Yes, NCT07674680 is actively recruiting participants. Contact the research team at limberglab@missouri.edu for enrollment information.
Where is the NCT07674680 trial being conducted?
This trial is being conducted at Columbia, United States.
Who is sponsoring the NCT07674680 clinical trial?
NCT07674680 is sponsored by University of Missouri-Columbia. The trial plans to enroll 60 participants.